Becker Muscular Dystrophy - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 40 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Becker Muscular Dystrophy - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Becker Muscular Dystrophy - Pipeline Review, H2 2014', provides an overview of the Becker Muscular Dystrophy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Becker Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Becker Muscular Dystrophy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Becker Muscular Dystrophy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Becker Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Becker Muscular Dystrophy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Becker Muscular Dystrophy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Becker Muscular Dystrophy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Becker Muscular Dystrophy Overview 6
Therapeutics Development 7
Pipeline Products for Becker Muscular Dystrophy - Overview 7
Pipeline Products for Becker Muscular Dystrophy - Comparative Analysis 8
Becker Muscular Dystrophy - Therapeutics under Development by Companies 9
Becker Muscular Dystrophy - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Becker Muscular Dystrophy - Products under Development by Companies 13
Becker Muscular Dystrophy - Companies Involved in Therapeutics Development 14
PTC Therapeutics, Inc. 14
ReveraGen BioPharma, Inc. 15
Sarepta Therapeutics, Inc. 16
Sphaera Pharma Pvt. Ltd. 17
Becker Muscular Dystrophy - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
AAV1-FS-344 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ataluren - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
CRD-007 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
epicatechin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecule for Becker Muscular Dystrophy - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Becker Muscular Dystrophy - Recent Pipeline Updates 33
Becker Muscular Dystrophy - Dormant Projects 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products under Development for Becker Muscular Dystrophy, H2 2014 7
Number of Products under Development for Becker Muscular Dystrophy - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Becker Muscular Dystrophy - Pipeline by PTC Therapeutics, Inc., H2 2014 14
Becker Muscular Dystrophy - Pipeline by ReveraGen BioPharma, Inc., H2 2014 15
Becker Muscular Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H2 2014 16
Becker Muscular Dystrophy - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 20
Number of Products by Stage and Route of Administration, H2 2014 22
Number of Products by Stage and Molecule Type, H2 2014 24
Becker Muscular Dystrophy Therapeutics - Recent Pipeline Updates, H2 2014 33
Becker Muscular Dystrophy - Dormant Projects, H2 2014 38